Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

Rhea-AI Summary

Immutep has announced that the first patient has been enrolled and dosed in the INSIGHT-003 trial, evaluating a triple combination therapy for metastatic non-small cell lung carcinoma. This innovative approach combines Immutep’s lead product candidate, eftilagimod alpha (efti), with standard chemotherapy and anti-PD-1 therapy. The trial aims to recruit up to 20 patients, with initial results expected in 2022, marking a significant milestone in cancer treatment research.

Positive

• First patient enrolled in INSIGHT-003 trial, indicating progress in clinical development.
• The trial investigates a novel triple combination therapy with potential to enhance efficacy in treating cancer.

Negative

• None.

Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep’s lead product candidate eftilagimod alpha (efti or IMP321).

INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and anti-PD-1 therapy. The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022.

CSO and CMO Dr. Frédéric Triebel said: “INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered. We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity. Dosing the first patient in this trial is a significant milestone and it sets the wheels in motion for reporting first data which are currently anticipated in 2022.”

About INSIGHT-003
INSIGHT-003 is an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being run as the third arm (Stratum C) of the ongoing phase 1 INSIGHT trial with Prof. Dr. Salah-Eddin Al-Batran as lead investigator.

Up to 20 patients with solid tumours will be recruited to participate in the trial. Patients will receive 30 mg subcutaneous doses of efti every two weeks in conjunction with standard of care chemotherapy plus anti-PD-1 therapy. The trial will assess the safety, tolerability and initial efficacy of the combination.

About Immutep

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

FAQ

What is the INSIGHT-003 trial by Immutep and what does it evaluate?

The INSIGHT-003 trial evaluates a triple combination therapy of Immutep's eftilagimod alpha, chemotherapy, and anti-PD-1 therapy for metastatic non-small cell lung carcinoma.

When are the initial results of the INSIGHT-003 trial expected?

Initial results from the INSIGHT-003 trial are expected in the calendar year 2022.

How many patients will be recruited for the INSIGHT-003 trial?

Up to 20 patients with solid tumors will be recruited for the INSIGHT-003 trial.

What is the significance of dosing the first patient in INSIGHT-003?

Dosing the first patient in INSIGHT-003 represents a significant milestone in the trial's progress and the development of new cancer therapies.